Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

Application value of Tacrolimus sustained-release capsules in patients after liver transplantation

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Lower Tacrolimus Trough Levels in the Late Period after Living Donor Liver Transplantation Contribute to Improvements in Long-Term Clinical Outcomes.

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.

Higher Tacrolimus Blood Concentration is Related to Hyperlipidemia in Living Donor Liver Transplantation Recipients

A Retrospective Analysis of the Safety and Efficacy of Low Dose Tacrolimus (fk506) for Living Donor Liver Transplant Recipients

Characteristics of Recipients with Complete Immunosuppressant Withdrawal after Adult Liver Transplantation

Metabolic characteristics and usage of tacrolimus in patients subject to living-donor partial liver transplantation

''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Efficacy and safety of extended -release versus standard -release tacrolimus in liver transplant recipients:A systematic review

Comparison between standard-release and extended-release tacrolimus in lung transplantation

Using Tacrolimus,mycophenolate and Senipen for No-Hormone Immunosuppressive Therapy after Liver Transplantation

Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study

Clinical Research of Domestic Tacrolimus in Management of Rejection Following Renal Transplant

Non-linear Relationship between Tacrolimus Blood Concentration and Acute Rejection After Kidney Transplantation: A Systematic Review and Dose-Response Meta-Analysis of Cohort Studies

Reappraisal of tacrolimus levels after liver transplant for HCC: A multicenter study toward personalized immunosuppression regimen

Extended release formulation of tacrolimus: efficacy and safety in stable liver transplant recipients

Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

[Dual, triple, and quadruple oral tacrolimus-based immunosuppression regimens after orthotopic liver transplantation: a randomised comparative study of regimens].

Long-term curative effect of tacrolimus in kidney transplantation patients in China:Meta-analysis